Phase IIa Study Evaluating AZD7798 in Crohn's Disease
Status:
RECRUITING
Trial end date:
2027-08-02
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.